COMPARATIVE STUDY OF CLOPIDOGREL VS PRASUGREL IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (PCI)
DOI:
https://doi.org/10.54112/bcsrj.v2024i1.1118Keywords:
Antiplatelet therapy, clopidogrel, elective PCI, prasugrel, stent thrombosis, thrombosisAbstract
Antiplatelet therapy is a cornerstone in managing patients undergoing percutaneous coronary intervention (PCI) to prevent thrombotic complications. Prasugrel and clopidogrel are two commonly used agents, but their comparative efficacy and safety remain a subject of ongoing research, particularly in elective PCI cases. Objective: This study aimed to compare the safety and efficacy of prasugrel and clopidogrel in patients undergoing elective PCI, focusing on clinical outcomes such as minor and major bleeding, stent thrombosis, and mortality. Methods: This retrospective cohort study was conducted at a tertiary care hospital in Pakistan between January and July 2024. A total of 200 patients undergoing elective PCI were included in the study. Patients received either clopidogrel (300 mg or 600 mg) or prasugrel (60 mg) as part of their antiplatelet therapy. Clinical outcomes were assessed, including minor and major bleeding, thrombosis, and death. Statistical analyses were performed using Pearson correlations, chi-square tests, and regression analysis. SPSS software (version 25.0) was used for data analysis, with statistical significance set at p < 0.05. Results: Of the 200 patients, 48.5% were male, and 51.5% were female, with the majority aged between 61 and 70. Prasugrel (60 mg) was the most commonly used loading dose (35.5%). Minor bleeding events were significantly higher in the prasugrel group compared to the clopidogrel group (p = 0.05). However, no significant differences were observed in major bleeding, stent thrombosis, or mortality between the two groups. A positive correlation between minor bleeding and stent thrombosis was noted (p = 0.048), while regression analysis confirmed that prasugrel did not significantly increase the risk of major bleeding or death. Conclusion: Prasugrel was associated with a higher incidence of minor bleeding compared to clopidogrel, but both agents exhibited comparable safety profiles in terms of major bleeding, thrombosis, and mortality in patients undergoing elective PCI. The findings suggest that prasugrel can be considered a safe and effective alternative to clopidogrel in elective PCI, with careful patient selection to minimize bleeding risks.
Downloads
References
ouli, M., Di Biase, L., Natale, A., Rihal, C. S., Holmes, D. R., Asirvatham, S., . . . Friedman, P. A. (2023). Nonthrombogenic roles of the left atrial appendage: JACC review topic of the week. Journal of the American College of Cardiology, 81(11), 1063-1075.
Gurbel, P. A., Jeong, Y.-H., & Tantry, U. S. (2019). Phosphodiesterase inhibitors Platelets (pp. 979-989): Elsevier.
Kang, D.-H., Park, S.-J., Rim, J. H., Yun, S.-C., Kim, D.-H., Song, J.-M., . . . Lee, J.-W. (2010). Early surgery versus conventional treatment in asymptomatic very severe aortic stenosis. Circulation, 121(13), 1502-1509.
Koskinas, K. C., Siontis, G. C., Piccolo, R., Franzone, A., Haynes, A., Rat-Wirtzler, J., . . . Räber, L. (2016). Impact of diabetic status on outcomes after revascularization with drug-eluting stents in relation to coronary artery disease complexity: patient-level pooled analysis of 6081 patients. Circulation: Cardiovascular Interventions, 9(2), e003255.
Kubo, M., Kiyohara, Y., Kato, I., Tanizaki, Y., Arima, H., Tanaka, K., . . . Iida, M. (2003). Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke, 34(10), 2349-2354.
Santos-Gallego, C. G., & Badimon, J. (2021). Overview of aspirin and platelet biology. The American journal of cardiology, 144, S2-S9.
Schüpke, S., Neumann, F.-J., Menichelli, M., Mayer, K., Bernlochner, I., Wöhrle, J., . . . Antoniucci, D. (2019). Ticagrelor or prasugrel in patients with acute coronary syndromes. New England journal of medicine, 381(16), 1524-1534.
Sibbing, D., Aradi, D., Jacobshagen, C., Gross, L., Trenk, D., Geisler, T., . . . Kiss, R. G. (2017). Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. The lancet, 390(10104), 1747-1757.
Singh, S., Singh, M., Grewal, N., & Khosla, S. (2016). Comparative efficacy and safety of prasugrel, ticagrelor, and standard-dose and high-dose clopidogrel in patients undergoing percutaneous coronary intervention: a network meta-analysis. American Journal of Therapeutics, 23(1), e52-e62.
Stewart, J. A. (2021). In-hospital resuscitation of Covid-19 patients is impeded by serious delays, but the problem is obscured by poor time data. European heart journal, 42(15), 1528-1529.
Tofield, A. (2019). New corrected 2018 Impact Factor of the European Heart Journal is 24.899: Oxford University Press.
Valgimigli, M., Bueno, H., Byrne, R. A., Collet, J.-P., Costa, F., Jeppsson, A., . . . Mauri, L. (2018). 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). European heart journal, 39(3), 213-260.
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., . . . Murphy, S. A. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England journal of medicine, 357(20), 2001-2015.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 N PERVEZ , MA KHAN , FU REHMAN , AG KHAN , M HASHIM , SA BARI, A QADEER, SU KAKAR
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
